Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jean-Paul Clozel M.D. | CEO & Exec. Director | 1.38M | -- | 1955 |
| Mr. André C. Muller | Exec. VP & CFO | -- | -- | 1963 |
| Dr. Martine Clozel | Exec. VP & Chief Scientific Officer | -- | -- | 1955 |
| Mr. Andrew C. Weiss | Sr. VP and Head of Investor Relations & Corp. Communications | -- | -- | 1968 |
| Mr. Julien Gander L.L.M. | Sr. VP, Group Gen. Counsel & Company Sec. | -- | -- | 1979 |
| Mr. Alexander Khatuntsev | Sr. VP & Head of Global HR | -- | -- | 1978 |
| Dr. Guy Braunstein M.D. | Exec. VP & Chief Medical Officer | -- | -- | 1956 |
| Mr. Olivier Lambert | Sr. VP and Head of Global Pharmaceutical Devel. & Quality Assurance | -- | -- | 1966 |
| Mr. Markus A. Riederer | Sr. VP & Head of Drug Discovery Biology | -- | -- | 1962 |
| Mr. Christoph Boss | Sr. VP & Head of Drug Discovery Chemistry | -- | -- | 1968 |
Idorsia Ltd
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Corporate Governance
Upcoming Events
February 27, 2025 at 6:00 AM UTC
Idorsia Ltd Earnings Date
Recent Events
Recent Events Information Not Available